IL-22 treatment significantly reduced the number of inflammatory cells and pro-inflammatory cytokine levels (such as IL-6, TNF-α, and G-CSF) in bronchoalveolar lavage (BAL) fluid, while also decreasing the pathological damage score of lung tissue. This suggests that IL-22 has therapeutic potential for ARDS. The gene discussed is TNF; the disease is acute respiratory distress syndrome.